Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Development of bisphosphonates].

Kiyoshi Nakatsuka1

  • 1Department of Endocrinology, Metabolism, and Molecular Medicine, Osaka City University Graduate School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|March 18, 2003
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Effects of raloxifene treatment on the structural geometry of the proximal femur in Japanese women with osteoporosis.

Journal of bone and mineral metabolism·2010
Same author

Clinical and biochemical response of TNFRSF11A-mediated early-onset familial Paget disease to bisphosphonate therapy.

Calcified tissue international·2008
Same author

Guidelines for diagnosis and management of Paget's disease of bone in Japan.

Journal of bone and mineral metabolism·2006
Same author

[Bone and bone related biochemical examinations. Bone and collagen related metabolites. Measurement of PICP and PINP in the evaluation of pharmaceutical treatment efficacy for osteoporosis].

Clinical calcium·2006
Same author

Prevalence and clinical features of Paget's disease of bone in Japan.

Journal of bone and mineral metabolism·2006
Same author

[Use of metabolic bone markers in clinical setting].

Clinical calcium·2005

Bisphosphonates (BPs) are key osteoporosis treatments. Research is exploring convenient BP administration and new uses for bone diseases like cancer metastases.

Area of Science:

  • Pharmacology
  • Bone Biology
  • Drug Development

Context:

  • Bisphosphonates (BPs) are established antiresorptive agents widely used for osteoporosis treatment.
  • Newer generation BPs, alendronate and risedronate, were approved in Japan in 2001 and 2002.
  • Ongoing research focuses on convenient administration routes and schedules for individual patients.

Purpose:

  • To review the established and emerging applications of bisphosphonates.
  • To highlight advancements in bisphosphonate therapy for osteoporosis and other bone disorders.
  • To explore potential new indications for bisphosphonates.

Summary:

  • Bisphosphonates are first-line treatments for osteoporosis with proven antifracture efficacy.
  • Beyond osteoporosis, BPs are indicated for Paget's disease and hypercalcemia of malignancy.

Related Experiment Videos

  • Extended indications for metastatic bone diseases (breast cancer, multiple myeloma) and rheumatoid arthritis are under development.
  • First-generation bisphosphonates like etidronate show promise for ectopic ossification and calcification due to mineralization inhibition.

    • Impact:

    • Improved patient compliance through convenient administration.
    • Expanded therapeutic options for various bone-related conditions.
    • Potential for novel treatments targeting mineralization and ectopic calcification.